Top 10 Viewed Abstracts from ASCO 2013

Google+ Pinterest LinkedIn Tumblr +

ASCO 2013 600 x 300You can search ASCO’s comprehensive database of abstracts to find the results of the latest clinical cancer research.  The 2013 Annual Meeting abstracts are now available on the ASCO website.

 Here we have a selection of the 10 most viewed Abstracts from this years conference.

 

 

MOST VIEWED ABSTRACTS

  1. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (2012 ASCO Annual Meeting )

  2. A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study. (2012 ASCO Annual Meeting )

  3. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. (2012 ASCO Annual Meeting )

  4. Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer. (2012 ASCO Annual Meeting )

  5. Outcomes and efficiency of national gastric cancer screening program in Korea: Single-center, large-scale study. (2012 Gastrointestinal Cancers Symposium )

  6. Outcomes and efficiency of national gastric cancer screening program in Korea: Single-center, large-scale study. (2012 Gastrointestinal Cancers Symposium )

  7. Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. (2012 ASCO Annual Meeting )

  8. Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. (2012 ASCO Annual Meeting )

  9. Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey. (2012 ASCO Annual Meeting )

  10. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. (2012 ASCO Annual Meeting )

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.